Ann Kristin Led is stepping down as CEO of MedTrace as the company sharpens its focus on expanding its presence in the United States. Nicholas Borys M.D., Chief Medical Officer, will assume the role of Interim CEO effective as of 12th June.
The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its cell and gene therapy office on administrative leave and escorted her out of the agency. In recent months, multiple biotechs have responded to analyst questions about changes at the FDA by praising Verdun and highlighting the continuity she provided.
Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, for $561 million up front, with the hope that it can help transform a newly launched treatment for postpartum depression (PPD) into the indication’s standard of care.
In a press release Thursday, UCB revealed a plan to establish a “new, state-of-the-art biologics manufacturing facility in the United States.” The company hasn’t settled on the exact location, but it says the site will create 300 high-skilled jobs once complete.
Schott Pharma has expanded its Lukácsháza site with a new facility for prefillable glass syringes, which are used for GLP-1 therapies, vaccines, and biologics. Since opening in June 2024, the site has added 120 employees, begun production, and increased capacity.
